Download the white paper for practical insights into how manufacturers are approaching AI adoption in regulated environments and the controls required to support it responsibly.

Artificial intelligence (AI) is quickly becoming part of the conversation across pharmaceutical manufacturing, but in cGMP environments, the question is no longer whether AI has potential. It’s where it can realistically deliver value without introducing new operational or compliance risk.

Many manufacturers are still managing deviations, CAPA workflows, and performance monitoring through disconnected systems and manual review. As data volumes continue to grow, teams are increasingly challenged to turn that information into actionable operational insight fast enough to support real-time decision-making.

That’s where AI is beginning to gain traction.

In our latest white paper, AI in cGMP Manufacturing, Project Farma experts Joe O’Brien, VP of Digital Transformation & Automation, and Jim Rice, VP, Client Engagement, explore how AI is being evaluated and applied within regulated manufacturing environments, including:

• Reducing the burden of manual data review
• Detecting process shifts earlier
• Supporting smarter scheduling and resource planning
• Strengthening deviation management and CAPA workflows
• Applying lifecycle oversight and risk-based governance principles

The white paper also examines the realities that come with implementation in cGMP settings, including validation expectations, data integrity requirements, explainability, traceability, and the continued importance of SME oversight.

For organizations evaluating where AI may fit within manufacturing operations, understanding the operational constraints is just as important as understanding the technology itself.